Kynurenine 3-Monooxygenase (Kynurenine 3 Monooxygenase)

An NADPH-dependent flavin monooxygenase that plays a key role in the catabolism of TRYPTOPHAN by catalyzing the HYDROXYLATION of KYNURENINE to 3-hydroxykynurenine. It was formerly characterized as EC 1.14.1.2 and EC 1.99.1.5.

Also Known As:

Networked: 75 relevant articles (4 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Giorgini, Flaviano: 9 articles (01/2021 - 05/2005)
2.	Schwarcz, Robert: 9 articles (01/2019 - 07/2005)
3.	Mole, Damian J: 5 articles (01/2019 - 02/2015)
4.	Webster, Scott P: 5 articles (01/2019 - 02/2015)
5.	Erhardt, Sophie: 5 articles (01/2018 - 04/2011)
6.	Hoshi, Masato: 4 articles (11/2021 - 01/2017)
7.	Saito, Kuniaki: 4 articles (11/2021 - 01/2017)
8.	Lin, Chen-Si: 4 articles (09/2021 - 01/2019)
9.	Binnie, Margaret: 4 articles (01/2019 - 09/2016)
10.	Engberg, Göran: 4 articles (01/2018 - 04/2011)

Related Diseases

1.	Dyskinesias (Dyskinesia) 09/30/2003 - "The antidystonic efficacy of Ro 61-8048 at well-tolerated doses suggests that kynurenine 3-hydroxylase inhibitors should be considered as new therapeutic candidates for the treatment of dyskinesias." 01/25/2008 - "Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys." 05/31/2008 - "In the present study, intrastriatal injections of Ro 61-8048 (60-80 microg/hemisphere) significantly reduced the severity of dystonia in dt(sz) hamsters, suggesting that kynurenine 3-hydroxylase inhibitors may be interesting candidates for managing dyskinesias which are related to striatal dysfunction." 06/01/2009 - "In a second experiment, a kynurenine 3-hydroxylase inhibitor Ro 61-8048, combined with L-DOPA/Benserazide, reduced dyskinesias in MPTP monkeys. " 01/01/2010 - "Chronic treatment with Ro 61-8048 a kynurenine hydroxylase inhibitor, docosahexaenoic acid (DHA) a polyunsaturated fatty acid (omega-3), naltrexone an opioidergic antagonist and CI-1041 an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist with L-DOPA prevented dyskinesias to various extents except naltrexone whereas all MPTP monkeys treated with L-DOPA alone developed dyskinesias. "
2.	Dystonia (Limb Dystonia) 09/30/2003 - "The effects of the novel kynurenine 3-hydroxylase inhibitor 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide (Ro 61-8048) on severity of dystonia were examined in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress precipitates dystonic episodes. " 05/31/2008 - "Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant." 09/30/2003 - "The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia." 05/31/2008 - "In the present study, intrastriatal injections of Ro 61-8048 (60-80 microg/hemisphere) significantly reduced the severity of dystonia in dt(sz) hamsters, suggesting that kynurenine 3-hydroxylase inhibitors may be interesting candidates for managing dyskinesias which are related to striatal dysfunction."
3.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/2019 - "A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites." 01/01/2018 - "Kynurenine 3-monooxygenase (KMO) inhibitors have been developed for the treatment of neurodegenerative disorders. " 01/01/2019 - "Inhibition of the enzyme kynurenine 3-monooxygenase (KMO) in the KP normalises these metabolic imbalances and ameliorates neurodegeneration and related phenotypes in several neurodegenerative disease models. " 02/01/2015 - "Human kynurenine 3-monooxygenase (KMO) is emerging as an important drug target enzyme in a number of inflammatory and neurodegenerative disease states. " 01/01/2018 - "Kynurenine 3-monooxygenase (KMO) is a well-validated therapeutic target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Huntington's disease (HD). "
4.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 07/01/1999 - "A significant reduction in infarct volumes also was found when the kynurenine hydroxylase inhibitors were given to rats after permanent middle cerebral artery occlusion (from 207+/-111 mm3 in vehicle-treated rats to 82+/-18 and to 62+/-57 mm3 in rats treated with mNBA, 400 mg/kg intraperitoneally, or with Ro 61-8048, 40 mg/kg intraperitoneally, respectively). " 07/01/1999 - "Two kynurenine hydroxylase inhibitors, (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfona mide (Ro 61-8048), have been tested as neuroprotective agents on brain lesions induced by bilateral carotid occlusion in gerbils or by middle cerebral artery occlusion in rats. "
5.	Infarction (Infarctions) 07/01/1999 - "A significant reduction in infarct volumes also was found when the kynurenine hydroxylase inhibitors were given to rats after permanent middle cerebral artery occlusion (from 207+/-111 mm3 in vehicle-treated rats to 82+/-18 and to 62+/-57 mm3 in rats treated with mNBA, 400 mg/kg intraperitoneally, or with Ro 61-8048, 40 mg/kg intraperitoneally, respectively). "

Related Drugs and Biologics

1.	Ro 61-8048
2.	Enzymes
3.	Kynurenine
4.	kynureninase
5.	Tryptophan (L-Tryptophan)
6.	Kynurenic Acid (Kynurenate)
7.	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)
8.	Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)
9.	Benzenesulfonamides
10.	Biomarkers (Surrogate Marker)

Related Therapies and Procedures

1.	Injections
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Therapeutics